Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma

Abstract

Etk/Bmx is a cytoplasmic tyrosine kinase, which was first identified in human bone marrow cells. It has been found to play an important role in the regulation of differentiation and tumorigenicity in some cancers. The aim of this study was to investigate the significance of Etk/Bmx expression in hepatocellular carcinoma (HCC) and the relationship between Etk/Bmx and activated protein-1 (AP-1)- and nuclear factor-kappaB (NF-kappaB)-associated proteins. We used immunohistochemisty to examine 40 cases of human HCC along with corresponding nontumor tissues to assess Etk/Bmx, Jun family (c-Jun, JunB, JunD), Fos family (c-Fos, FosB, Fra-1) and NF-kappaB p65 expression in these samples. Etk/Bmx expression was present in 12 of 40 (30%) HCC specimens, 4 of which among the 25 well-differentiated tumors and 8 among the 15 poorly differentiated tumors, respectively. In contrast, 6 of 40 (15%) cases expressed Etk/Bmx in adjacent nontumor tissues. Expression level and cellular localization of Etk/Bmx were different in cancer cells and nontumor cells. Etk/Bmx expression was correlated with histological differentiation, but not with clinicopathological features including tumor size, HBV infection, cirrhosis, and metastasis. There was a close relationship between Etk/Bmx and c-Fos expression in HCC. Etk/Bmx immunopositivity was independent of c-Jun, JunD, FosB, Fra-1 and NF-kappaB p65. Our results indicated that Etk/Bmx may have different biological roles in tumor and nontumor cells, and may be involved in regulating hepatocyte differentiation by c-Fos activation in HCC.